Jake VanCampen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jake VanCampen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. Coleman
Knight Cancer Institute, Oregon Health & Science University
220 shared publications - Garth Kong
Knight Cancer Institute, Oregon Health & Science University
220 shared publications - Theodore P. Braun
Oregon Health & Science University
220 shared publications - William M. Yashar
Knight Cancer Institute, Oregon Health & Science University
220 shared publications - Brian James Druker
Knight Cancer Institute, Oregon Health & Science University, Portland, OR
219 shared publications - Brittany M. Curtiss
Knight Cancer Institute, Oregon Health & Science University, Portland, USA
219 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Single cell ATAC-seq cell population dynamics in primary patient samples follow-ing treatment with dual FLT3/LSD1 inhibition.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Single cell ATAC-seq cell population dynamics in primary patient samples follow-ing treatment with dual FLT3/LSD1 inhibition.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
RNA PolII Pause Index Analysis from MOLM13 RBP1 CUT&Tag (6 Hours After Drug Treatment)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
RNA PolII Pause Index Analysis from MOLM13 RBP1 CUT&Tag (6 Hours After Drug Treatment)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Log2 Normalized Counts of Differentially Expressed Genes from Primary AML Blast Bulk RNA-seq (24 Hours After Drug Treatment)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Log2 Normalized Counts of Differentially Expressed Genes from Primary AML Blast Bulk RNA-seq (24 Hours After Drug Treatment)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
SPI1 knockdown does not disrupt dual FLT3/LSD1 inhibition synergy.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 9 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
SPI1 knockdown does not disrupt dual FLT3/LSD1 inhibition synergy.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Epigenetic impact of dual FLT3/LSD1 inhibition.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Epigenetic impact of dual FLT3/LSD1 inhibition.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Drug synergy between FLT3 and LSD1 inhibitors in FLT3-ITD and FLT3-wildtype cell lines.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Drug synergy between FLT3 and LSD1 inhibitors in FLT3-ITD and FLT3-wildtype cell lines.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Normalized Read Pileup and Differential Enrichment Clusters of MOLM13 H3K27Ac CUT&Tag (6 Hours After Drug Treatment) at Enhancers and Promoters
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Normalized Read Pileup and Differential Enrichment Clusters of MOLM13 H3K27Ac CUT&Tag (6 Hours After Drug Treatment) at Enhancers and Promoters
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Excess over Bliss of Primary AML Blasts from 72 Patient Samples
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Excess over Bliss of Primary AML Blasts from 72 Patient Samples
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Super-Enhancer-Type Analysis of STAT5 ChIP-Seq Peaks (24 Hours After Drug Treatment).
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Super-Enhancer-Type Analysis of STAT5 ChIP-Seq Peaks (24 Hours After Drug Treatment).
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Combined FLT3/LSD1 inhibition does not substantially alter myeloid differentiation.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 8 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Combined FLT3/LSD1 inhibition does not substantially alter myeloid differentiation.